Navigation Links
New Drug Eases Asthma Symptoms
Date:10/18/2007

Blocks inflammatory activity of two immune system molecules, researchers report

THURSDAY, Oct. 18 (HealthDay News) -- A new twist on an old theory of drug treatment for asthma has shown promise in a small, early trial, a California company reports.

The idea is to block the activity of cytokines, immune system molecules believed to play a major role in asthma by causing allergic inflammation.

A number of cytokines have been implicated in asthma, among them interleukin-4 and interleukin-13. A number of drugs aimed at blocking one or the other have met with little success.

The new approach is a single drug, called pitrakinra, which blocks the receptors for both interleukins simultaneously, said Malinda Longphre, director of the clinical department of Aerovance Inc. in Berkeley.

"It has been shown that IL-4 shares receptors with IL-13," Longphre added. "They produce the same response. Our drug blocks the shared receptors, and it appears from the two clinical trials we report that we are able to intervene and inhibit the allergic response throughout."

Results of the two trials are reported in the Oct. 19 issue of The Lancet. In one trial, 12 people with asthma were given daily injections of pitrakinra and then inhaled allergens. One major measure of lung function, forced expiratory volume, was reduced by only 17.1 percent in those taking the drug, compared to a decrease in lung function of 23.1 percent in a group taking a placebo.

In the second study, 16 people with asthma inhaled pitrakinra. The decrease in lung function when exposed to allergens averaged a mere 4.4 percent, compared to a 15.9 percent decrease in lung function for a comparable group that was given placebo.

"The drug itself is human IL-4, with a couple of amino acid substitutions that allow it to bind to the receptors," Longphre explained. The company hopes to market the drug as an inhalant, but that prospect is years away and will require a long series of successful trials, she added.

"We see it as a treatment for problem patients, those not able to control the condition by steroid therapy," Longphre said. "Most doctors have at least one such patient in their practice."

The findings drew a mixed response from asthma experts.

Dr. Harold Nelson, a professor of medicine at the National Jewish Medical and Research Center in Denver, was downbeat, primarily because of his experience with an IL-4 blocker several years ago.

"A first study was fairly encouraging," Nelson said. "A second study was positive. A third study was an utter failure, and we dropped the drug."

And Nelson was not impressed by the nature of the Lancet studies. "These were allergen-challenge studies," he said. "An allergen-challenge study is not asthma. A positive response in an allergen-challenge study is not a positive response in asthma."

However, Dr. Marc E. Rothenberg, director of the division of allergy and immunology at Cincinnati Children's Hospital Medical Center, had a markedly different reaction.

"The idea that a drug can block this pathway and block the asthmatic reaction is very exciting," Rothenberg said.

While the two trials were small, "they were not insignificant," he added. "Such a dramatic effect with a small sample size indicates that the effect will not be trivial."

The new drug is a result of two decades of research, and "key targets have been identified through this molecular research," Rothenberg said.

Drug companies now are testing a number of drugs aimed at blocking cytokine activity in asthma, he added.

More information

For more on asthma and its treatment, consult the National Library of Medicine.



SOURCES: Malinda Longphre, Ph.D., director, clinical department, Aerovance Inc., Berkeley, Calif.; Harold Nelson, M.D., professor, medicine, National Jewish Medical and Research Center, Denver; Marc E. Rothenberg, M.D., director, division of allergy and immunology, Cincinnati Children's Hospital Medical Center; Oct. 19, 2007, The Lancet


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Evidence Links Protein Damage to Neurodegenerative diseases like Parkinsons and Alzheimers
2. Ticks may cause more diseases
3. Headache decreases appetite
4. Lifespan And Height Interlinked With Juvenile Diseases.
5. Increase in the Number of Cases of Animal Diseases in New South Wales.
6. Metronidazole Increases Risk Of Premature Deliveries.
7. Human gene number increases
8. Stress response increases suicide risk
9. Birth weight key factor in heart diseases
10. Sleep apnoea increases post-operative risks
11. New Drug ALT-711 decreases blood vessel stiffness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... Mt. Horeb, WI (PRWEB) , ... March 29, 2017 , ... ... her patients on early orthodontic treatment and accepting new pediatric patients, with or without ... can help young patients have a better orthodontic outcome and experience. When patients receive ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... oral braces. "The rubber bands used in conjunction with my braces always rubbed ... to design a way to prevent this problem." The O.B.S. was the result ...
(Date:3/29/2017)... PA (PRWEB) , ... March ... ... eastern suburbs and South Hills of Pittsburgh now have easier access to ... Pennsylvania only by Allegheny Health Network (AHN). Orthopaedic surgeons at Forbes Hospital ...
(Date:3/28/2017)... ... March 28, 2017 , ... A ... to improve teacher quality, the field must first improve teacher preparation program design. ... to the next” and that decades of input- and outcome-based research has failed ...
(Date:3/28/2017)... ... 2017 , ... Resoundant, Inc., the developer of Magnetic ... annual customer education symposium, a world-class learning conference that offers educational content designed ... 31, 2017 at the Atlanta Marriott Marquis in Atlanta, Georgia. , Innovations for ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... , March 29, 2017 Global intravenous (IV) iron ... billion by 2021, growing at a CAGR of 5%. ... by a doctor to treat anemia or other iron deficiencies. ... in the body. However, in some cases, oral administrations are ... and intravenous (IV) iron therapy comes into the picture. ...
(Date:3/29/2017)... March 29, 2017 Today, CVS Health officials (NYSE: ... Reynolds , Department of Public Health Director Gerd Clabaugh ... Lukan in announcing the availability of the opioid overdose-reversal ... in Iowa.  CVS Health has established a standing order with ... Pharmacy to expand access to the medication in the state.   ...
(Date:3/29/2017)... Calif. , March 29, 2017  Experts ... recognized remote monitoring devices like  Soberlink Systems  as ... The consensus paper, published in early 2017, concluded ... and valuable in managing patient recovery." ... the Journal of Addiction Medicine, detail a range ...
Breaking Medicine Technology: